As the proposed regulation of the co-biological equivalence test was stopped by the Regulatory Reform Committee, The consigned generics business has revived.

On the other hand, companies producing single generics that have claimed to regulate co-biological equivalence testing are concerned. They point out that there are many competitors in the market due to the activation of consigned generics, so there is no advantage of single-developed generics.

Since the pharmaceutical industry was divided in half with respect to this regulation, it seems that everyone cannot be satisfied unless a new system is introduced.

To this end, the generic exclusivity needs to be improved so tha